2023
Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use
Belzer A, Nguyen M, Talsania A, Haldas J, Smith J, Leventhal J. Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use. JAMA Dermatology 2023, 159: 109-111. PMID: 36416832, PMCID: PMC9685543, DOI: 10.1001/jamadermatol.2022.4466.Peer-Reviewed Original Research
2020
Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors
Coleman EL, Olamiju B, Leventhal JS. Potentially life-threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors. Oncology Reports 2020, 45: 891-898. PMID: 33650659, PMCID: PMC7859912, DOI: 10.3892/or.2020.7911.Peer-Reviewed Original ResearchConceptsSevere cutaneous adverse reactionsTyrosine kinase inhibitorsLife-threatening severe cutaneous adverse reactionsAcute generalized exanthematous pustulosisEpidermal growth factor receptorStevens-Johnson syndromeCutaneous adverse reactionsToxic epidermal necrolysisVascular endothelial growth factorGrowth factor receptorAnaplastic lymphoma kinasePlatelet-derived growth factorAdverse reactionsFibroblast growth factor receptorFactor receptorApplication of TKIsGrowth factorHuman epidermal growth factor receptorKinase inhibitorsGeneralized exanthematous pustulosisPotential cutaneous toxicityEndothelial growth factorExanthematous pustulosisEpidermal necrolysisCutaneous toxicityCutaneous immune-related adverse events to checkpoint inhibitors
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.Peer-Reviewed Original ResearchConceptsAdverse reactionsCheckpoint inhibitorsImmune-related adverse reactionsCheckpoint inhibitor therapyCutaneous adverse eventsOngoing cancer treatmentPD-1 inhibitorsCTLA-4 inhibitorsImmune checkpoint inhibitorsCutaneous adverse reactionsPD-L1 inhibitorsDevelopment of immunotherapySuch adverse reactionsImmunomodulatory therapyTreatment interruptionAssociated morbidityPatient comorbiditiesAdverse eventsCutaneous toxicityInhibitor therapyImmune statusHematologic malignanciesEarly recognitionCancer treatmentManagement guidelinesCutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist.
Tattersall IW, Leventhal JS. Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist. The Yale Journal Of Biology And Medicine 2020, 93: 123-132. PMID: 32226342, PMCID: PMC7087048.Peer-Reviewed Original ResearchMeSH KeywordsDermatologyDrug EruptionsHumansImmune Checkpoint InhibitorsMolecular Targeted TherapySkin NeoplasmsConceptsCutaneous irAEsImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitionImmune checkpoint inhibitorsPotential adverse eventsPotential prognostic significanceNumber of cancersOnly carcinogenesisCheckpoint inhibitorsAdverse eventsCutaneous toxicityInhibitor therapyCheckpoint inhibitionPrognostic significanceCommon siteClinical characterizationPrimary dermatosesIrAEsTherapeutic promiseTreatment of diseasesTherapyCancerTreatmentDermatologists
2019
The life-threatening eruptions of immune checkpoint inhibitor therapy
Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clinics In Dermatology 2019, 38: 94-104. PMID: 32197753, DOI: 10.1016/j.clindermatol.2019.10.015.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsAcute generalized exanthematous pustulosisSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeToxic epidermal necrolysisManagement of irAEsImmune checkpoint inhibitor therapyCell death ligand 1Generalized exanthematous pustulosisCheckpoint inhibitor therapyCutaneous adverse reactionsDeath ligand 1Life-threatening presentationCell death 1Cytotoxic T lymphocytesLife-threatening eruptionsDermatologic toxicitiesExanthematous pustulosisICPI therapyNeutrophilic dermatosisCheckpoint inhibitorsEpidermal necrolysisAdverse eventsCutaneous eruption
2018
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDrug EruptionsExanthemaFemaleHumansIpilimumabLichenoid EruptionsMaleMiddle AgedNivolumabRetrospective StudiesSkin NeoplasmsStevens-Johnson SyndromeWithholding TreatmentConceptsInflammatory eruptionsCheckpoint inhibitorsTherapeutic responseImmune checkpoint inhibitor therapySingle tertiary care centerSingle-institution retrospective analysisYale-New Haven HospitalCheckpoint inhibitor therapyTertiary care centerMinority of patientsInpatient dermatology serviceDegree of severityMost rashesInhibitor therapyRetrospective studyTopical treatmentEarly recognitionMedical recordsCare centerInflammatory reactionRetrospective analysisDermatology servicesImmunotherapyMean latencyGrade 2Atezolizumab‐associated vitiligo‐like leukoderma in a patient with transitional cell carcinoma
Turner N, Leventhal J. Atezolizumab‐associated vitiligo‐like leukoderma in a patient with transitional cell carcinoma. International Journal Of Dermatology 2018, 57: e90-e92. PMID: 30091457, DOI: 10.1111/ijd.14191.Peer-Reviewed Original ResearchBullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapy
2017
A 71‐year‐old man with a hemorrhagic vesicular eruption
Hamilton CE, King BA, Cowper SE, Hochster H, Leventhal JS. A 71‐year‐old man with a hemorrhagic vesicular eruption. International Journal Of Dermatology 2017, 57: 147-148. PMID: 29057466, DOI: 10.1111/ijd.13793.Peer-Reviewed Case Reports and Technical Notes
2013
Crystal deodorant‐induced axillary granulomatous dermatitis
Leventhal JS, Farhadian JA, Miller KE, Tlougan BE, Patel RR, Sanchez MR. Crystal deodorant‐induced axillary granulomatous dermatitis. International Journal Of Dermatology 2013, 53: e59-e60. PMID: 23621443, DOI: 10.1111/j.1365-4632.2012.05686.x.Peer-Reviewed Original ResearchSkin Conditions of Baseball, Cricket, and Softball Players
Farhadian JA, Tlougan BE, Adams BB, Leventhal JS, Sanchez MR. Skin Conditions of Baseball, Cricket, and Softball Players. Sports Medicine 2013, 43: 575-589. PMID: 23456491, DOI: 10.1007/s40279-013-0022-4.Peer-Reviewed Original Research